BARCELONA, Spain — For the first five months of 2007, the future of the Codelink bioarray platform looked bleak. GE Healthcare had pledged to help customers adopt other platforms, and shutter the business and sell off its assets should a buyer not be found. Then, a last-minute deal with Applied Microarrays in April secured the future of the platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.